The case for & against
Bull & Bear analysis
Bearish
Minerva Neurosciences (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases, particularly targeting the negative symptoms of schizophrenia. Their lead product, Roliparidone, aims to fulfill a significant unmet medical need in the psychiatry field, addressing issues that current treatments inadequately solve. The company's commitment to enhancing patient outcomes is evident in their ongoing pipeline initiatives and regulatory engagements, allowing them to position themselves effectively within the competitive landscape of CNS therapies.
Bull says
- ↑Roliparidone targets unmet negative schizophrenia symptoms, a major therapeutic gap.
- ↑FDA accepted NDA for standard review; no advisory committee, PDUFA Feb 26, 2024.
- ↑$36.1M cash as of Q1 23 funds operations through next 12 months.
- ↑Management exploring partnerships to support commercial launch and market reach.
- ↑Analysts target $10.33 price, implying ~128% upside from current levels.
- ↑Positive momentum and stability metrics may attract long-term investors.
Bear says
- ↓Q1 23 net loss $7M and negative profitability highlight weak financials.
- ↓FDA RTF on Phase IIb comparability raises delay risk via a Type C meeting.
- ↓Cash down from $60.9M to $36.1M YoY, straining runway if approval stalls.
- ↓Short interest ~1.19 reflects market doubt on execution and approval chances.
- ↓Competition from established CNS players could erode first-mover advantage.
- ↓Negative revision trends and elevated leverage pose long-term solvency risks.
Earnings Call · Q3 2021 · Mgmt. Guidance
Updated 09-03-2026bullish
Transcript signals
Bull points
- I think we have a really good set of data together because remember we recently or a few months ago now time is running we we have disclosed of the the results of the open label extension where I mean definitely you can see an improvement of negative symptoms but this is in parallel you have definitely some improvement in terms of positive symptoms or at minimum stability of positive symptoms staying at a very low level after monotherapy with voliparidone and if you remember we had an extremely low relapse rate.
- The data showed that both objectives were met, indicating substantial progress in our lead program, ROLI paradigm, towards submission of a new drug application (NDA) for roliparidone.
- Our cash position was strengthened significantly in January 2021 with the receipt of a $60 million upfront cash payment from Royalty Pharma in connection with Royalty Pharma's acquisition of the company's royalty interest in Celtorexin.
Bear points
- Last week, we announced that the FDA had denied the company's request for a pre-NDA meeting for roly-peridone and proposed that the type C guidance meeting would be more appropriate.
- Net loss was $9.2 million for the third quarter of 2021, or net loss per share of 22 cents, basic and diluted, as compared to a net loss of $8.1 million, or net loss per share of 19 cents, basic and diluted, for the third quarter of 2020.
- Net loss was $28.6 million for the nine months ended September 30, 2021, or net loss per share of 67 cents, basic and diluted, as compared to net income, of $9.3 million, or net income per share of 23 cents, based, again, alluded, for the nine months ended September 30th, 2020.
Read full transcript analysis ›